Bahrain pharmaceutical market to grow to $120mn in 2010

October 19, 2015

In BMIs Q210 Business Environment Ratings for the 17 countries of the MEA region, Bahrain has moved up one place to take fifth spot. This is despite the country's overall pharmaceutical market rating dropping by 1.5 points. However, due to the precipitous drop from South Africa falling 4 places and 4.5 points Bahrain has managed to edge up in the rankings. The potential returns from the market are constrained by the islands population of just 1mn. However, the low-risk economic and political climate and strong pharmaceutical-specific regulatory framework mean that Bahrain is one of the regions most attractive markets in terms of the risks to realisation of returns category.

Key Topics Covered:

Executive Summary

SWOT Analysis

Pharmaceutical Business Environment Ratings

Bahrain Market Summary

Regulatory Regime

Industry Developments

Industry Forecast Scenario

Competitive Landscape

Company Monitor

Country Snapshot: Bahrain Demographic Data


Forecast Tables

Companies Mentioned:

Al-Jishi Corporation Bahrain Industrial Pharmaceutical Co (Bidapharm) Behzad Medical Establishment Yousuf Mahmood Husain Company GlaxoSmithKline (GSK) Novartis Johnson & Johnson (J&J) Merck & Co Pfizer Sanofi-Aventis